(HNG) Humanin Review: Dosing, Benefits, and The Mitochondrial Link to Anti-Aging.

The discovery story tells you everything. In 2001, Nishimoto's lab in Japan was screening brain tissue from Alzheimer's patients, specifically looking at the unaffected regions; the parts of the brain that hadn't died yet. They were hunting for whatever factor was keeping those neurons alive while everything around them was degenerating.

What they found was Humanin. A tiny peptide, only 21 amino acids (24 if translated in the cytoplasm), encoded not in the nuclear genome where nearly every other protein comes from, but in the mitochondrial genome. In the 16S rRNA region. That's unusual enough on its own to make biologists pay attention.

Then came the longevity connection. Plasma Humanin levels decline measurably with age. And children of centenarians have significantly higher circulating Humanin than age-matched controls whose parents weren't long-lived.

The science is genuinely compelling. The human evidence gap is enormous.

Key Takeaways

• Humanin is a mitochondrially-derived peptide (MDP) encoded in the 16S rRNA region of mitochondrial DNA; one of the first functional peptides discovered in the mitochondrial genome
• Discovered in 2001 by Nishimoto et al. while screening for Alzheimer's neuroprotective factors
• HNG (S14G-Humanin), a single amino acid substitution analog, is approximately 1,000 times more potent than native Humanin. Most research and all community use involves HNG
• Centenarian offspring data: children of centenarians have measurably higher Humanin levels than controls. This is observational, not interventional; correlation, not causation
• Protects neurons, heart cells, pancreatic beta cells, and retinal cells from death in animal and cell models
• Works through multiple receptors including IGFBP-3 binding (blocking cell death signaling), the gp130/CNTFR/WSX-1 tripartite receptor complex, and FPR2
• Human interventional trials are essentially nonexistent as of April 2026
• Research chemical. Not approved anywhere

Humanin, In Simple Terms

• What mitochondria are: The energy factories inside every cell. They have their own small genome, separate from the DNA in your cell nucleus. Almost every protein your body makes is encoded in the nuclear genome. Humanin is one of the rare exceptions; it comes from mitochondrial DNA.
• Why that's unusual: The mitochondrial genome was thought to encode only 13 proteins, all related to energy production. Finding a survival peptide there was unexpected. It means your mitochondria aren't just making energy; they're sending survival signals to the rest of the cell.
• What Humanin does: In lab and animal studies, it protects cells from dying. Neurons exposed to Alzheimer's-related toxicity. Heart cells damaged by blood flow loss. Pancreatic cells attacked by inflammatory signals. The protection is broad, not tissue-specific.
• What HNG is: A modified version of Humanin where one amino acid (serine at position 14) is swapped for glycine. This tiny change makes it roughly 1,000 times more potent. If you see "Humanin" for sale, it's almost certainly HNG.
• The honest bottom line: The mitochondrial origin is fascinating; the centenarian data is a strong observational signal; the multi-tissue protection is real in preclinical models. However, no human interventional trials exist. The evidence gap rivals Dihexa.

Table of Contents

1. What is Humanin?
2. Mitochondrial origin: why it matters
3. MOTS-c, SHLPs, and the mitochondrial peptide family
4. How it works
5. HNG: the more potent analog
6. Dosing
7. What does the evidence show?
8. The centenarian data
9. Safety and side effects
10. What happens when you stop?
11. Legal status
12. Unanswered questions
13. Final take
14. FAQ

What is Humanin?

Humanin (MTRNR2) is a 21 or 24 amino acid peptide (depending on mitochondrial or cytoplasmic translation) encoded in the 16S ribosomal RNA region of mitochondrial DNA. It was discovered in 2001 by Hashimoto, Niikura, and Nishimoto at the Keio University School of Medicine in Japan while screening a cDNA library from the occipital cortex (back of the brain) of an Alzheimer's patient.

The name was chosen deliberately. Professor Nishimoto named it Humanin to reflect its potential to bring back "humanity" in Alzheimer's patients (editorial note: not that they lack it).

Humanin is found throughout the body: brain, plasma, skeletal muscle, heart, liver, kidney, testes, and retina. Plasma levels decline with age in mice, monkeys, and humans. Long-lived Ames dwarf mice have 50% higher circulating Humanin; short-lived GH-transgenic mice have lower levels.

Mitochondrial Origin: Why It Matters

Almost every protein and peptide in your body is encoded in nuclear DNA. The mitochondrial genome was thought to encode only 13 proteins, all components of the electron transport chain (the energy production machinery). Finding a survival-signaling peptide encoded there was a conceptual surprise.

Here's why it matters for aging: mitochondrial dysfunction is a hallmark of aging. As mitochondria decline, their output changes. Humanin is mitochondrially encoded and its levels decline with age. The connection is mechanistically coherent: as your mitochondria become less functional, they produce less of the survival signal that protects your cells from dying.

This positions Humanin differently from nuclear-encoded peptides. Its biology is directly tied to the organelle most central to cellular aging.

MOTS-c, SHLPs, and the Mitochondrial Peptide Family

Humanin isn't alone. An in silico (computer-based) search of the same mitochondrial region revealed six additional small peptides, named SHLP1 through SHLP6 (Small Humanin-Like Peptides). SHLP2 shares Humanin's anti-apoptotic (anti-cell-death) and neuroprotective properties. SHLP2 levels also decline with age.

MOTS-c is another MDP from the mitochondrial genome, encoded in the 12S rRNA region. It focuses on metabolic regulation (exercise mimetic effects, insulin sensitivity) rather than cytoprotection. It's a distinct compound with a different mechanism, sometimes discussed alongside Humanin because they're both MDPs.

The existence of this family; Humanin, SHLPs, MOTS-c; confirms the mitochondrial genome encodes a functional class of signaling peptides, not just energy machinery. That's a significant conceptual shift in mitochondrial biology.

How Humanin Works

Humanin acts through multiple pathways, which is unusual for a 21-amino-acid peptide.

IGFBP-3 binding and apoptosis inhibition: Humanin binds IGFBP-3 (insulin-like growth factor binding protein 3) with high affinity. IGFBP-3 independently promotes cell death in certain contexts. Humanin blocks this by interfering with IGFBP-3's nuclear import. This was confirmed in vivo by co-immunoprecipitation from mouse testes. In primary neurons, IGFBP-3 and Humanin actually work synergistically to protect against amyloid-beta toxicity; a result that surprised the researchers.

Bax interaction: Humanin binds and inhibits Bax, a pro-apoptotic protein that triggers mitochondrial cell death pathways. It prevents Bax from translocating to mitochondria and releasing cytochrome c (the cell death trigger).

Tripartite receptor complex: Extracellularly, Humanin activates a cell-surface receptor complex involving gp130, CNTFR-alpha, and WSX-1. This activates the JAK/STAT3 signaling pathway, a major cell survival route. Old mice (but not young mice) injected with Humanin showed increased phosphorylation of AKT and ERK1/2 specifically in the hippocampus; suggesting an age-dependent, brain-region-specific effect.

FPR2 receptor (formerly FPRL1): Humanin also acts through formyl peptide receptor 2, mediating anti-inflammatory signaling.

ApoE4 relevance: ApoE4 is the most significant genetic risk factor for Alzheimer's disease. Humanin has been studied for protection against ApoE4-induced neurotoxicity, connecting the survival peptide directly to the most common Alzheimer's risk genotype.

HNG: The More Potent Analog

Native Humanin is active. But HNG (S14G-Humanin), created by substituting glycine for serine at position 14, is approximately 1,000 times more potent in neuroprotection and cytoprotection assays.

This single amino acid change fundamentally shifts the practical landscape. Research has largely moved to HNG. Community use exclusively involves HNG. The Yen et al. (2020) longevity study in Aging used biweekly HNG injections in middle-aged mice and found improved metabolic healthspan parameters and reduced inflammatory markers.

The mechanism appears identical to native Humanin, just dramatically amplified. Whether subtle differences exist at higher potencies is not fully characterized.

What this means for dosing: You cannot convert native Humanin doses to HNG doses by simple arithmetic. The 1,000-fold potency difference means HNG doses should be substantially lower. Community dosing protocols are extrapolated from animal data with no human pharmacokinetic validation.

Humanin Dosing

What animal studies used: The Yen et al. study used HNG injections twice weekly in middle-aged mice. Other animal studies have used intracerebroventricular (directly into the brain) or intraperitoneal routes at varying doses.

Community protocols: Typically 1 to 5 mg HNG subcutaneous injection or intranasal, 2 to 5 times per week. These are extrapolations from animal research. No human dose-response data exists.

Route: Subcutaneous injection and intranasal are primary. Oral bioavailability is very poor; peptides are degraded in the GI tract.

Talk to a clinician. Human dosing is genuinely unknown.

What Does the Humanin Evidence Show?

Alzheimer's and Neuronal Protection

The founding application. Humanin rescued neurons from death induced by mutant amyloid precursor protein (APP), presenilin mutations (familial Alzheimer's genes), and amyloid-beta toxicity. Importantly, it did not protect against Huntington's disease or ALS models; the protection was specific to Alzheimer's-related insults. A Humanin derivative reduced amyloid-beta accumulation and improved memory in triple-transgenic Alzheimer's mice.

Cardiovascular Protection

Humanin preserves endothelial function and prevents atherosclerotic plaque progression in animal models. Circulating Humanin levels are associated with preserved coronary endothelial function in human observational data.

Diabetes and Beta Cell Protection

Humanin improves both hepatic and peripheral insulin sensitivity via hypothalamic STAT-3 activation. The HNGF6A analog (a non-IGFBP-3-binding variant) enhanced glucose-stimulated insulin secretion in isolated islets and cultured beta cells. This connects Humanin to Type 2 diabetes treatment through both insulin sensitivity and secretion pathways.

Male Fertility

Humanin is expressed in testes and spermatogenic cells. The IGFBP-3/Humanin interaction was confirmed in vivo in mouse testes. Research into sperm function and protection exists but is early-stage.

Retinal Protection

Humanin is expressed in retinal cells and has been studied for protection against age-related macular degeneration-related cell death.

The Human Evidence Gap

As of April 2026, essentially no published human interventional trial data exists for Humanin or HNG. The evidence base is animal studies, cell culture work, and human observational data. The centenarian correlation is the strongest human signal and it is observational, not interventional.

Humanin: The Centenarian Data

This deserves its own section because it's the most striking human observation.

Research from the Cohen lab, published in Aging (2020), measured circulating Humanin in offspring of centenarians compared to age-matched controls. The finding: children of centenarians had significantly higher Humanin levels. These are people with a statistically greater chance of becoming centenarians themselves.

Additionally, naked mole-rats (a model of negligible senescence; they barely age) maintain stable Humanin levels over decades, while mice show declining levels over their first 16 months.

What this shows: Humanin levels correlate with longevity across species and within human cohorts with known longevity advantage.

What it cannot show: Whether raising Humanin levels through supplementation would reproduce the longevity benefit. Correlation is not causation. The centenarians' children may have higher Humanin because of broader mitochondrial health, genetic factors, or other variables that independently promote longevity.

It's a signal, not a proof. But it's a specific, published, replicated signal from a credible research group.

Safety and Side Effects of Humanin

No significant adverse events reported in animal studies across multiple disease models. A comprehensive review of preclinical models noted that Humanin and its analogues generally demonstrate neuroprotective and cytoprotective effects without significant toxicity in short-term animal studies.

Community reports are limited given the niche user base. The HNG potency (1,000x native) means dosing errors carry more consequence. The genuinely unknown long-term profile in humans is the primary safety concern.

What Happens When You Stop Humanin?

No dependency or withdrawal reported. Cytoprotective effects likely fade as levels return to baseline. Whether any structural cellular effects from long-term use persist after discontinuation is unknown. This is a more nuanced question than simple dependency; if Humanin prevented cell death during treatment, those cells still exist. But the ongoing protective signaling stops.

Legal Status of Humanin

Research chemical everywhere. No drug approval anywhere. No currently visible regulatory pathway, though the Alzheimer's application and centenarian data create theoretical justification for clinical development.

Unanswered Questions

1. Will human Alzheimer's trials follow the animal data? The mechanistic case is strong. The centenarian data adds urgency. No registered trials exist as of April 2026.
2. Does the centenarian correlation translate to interventional benefit? Unknown. This is the billion-dollar question.
3. What is the actual safe and effective human dose range for HNG? Completely unknown.
4. How does IGFBP-3 interaction affect IGF-1 signaling at supplemental doses? IGFBP-3 regulates IGF-1 bioavailability. Humanin binding to IGFBP-3 could theoretically alter IGF-1 dynamics in ways that haven't been characterized at supplemental doses.
5. Does mitochondrial function need to be intact for Humanin to work? If Humanin's effects depend on mitochondrial health, does supplementing it in someone with severely dysfunctional mitochondria produce the same benefits?

Final Take

Humanin is one of the most scientifically interesting compounds on this site. The mitochondrial origin is genuinely unusual. The multi-tissue cytoprotection is well-characterized in preclinical work. The centenarian data is a compelling, published, replicated human signal from a credible research group. And the connection between mitochondrial decline, Humanin decline, and aging is mechanistically coherent.

But the human evidence gap is as large as Dihexa's. No interventional trials. No pharmacokinetic data. No dose-response characterization. The HNG potency makes community dosing genuinely uncertain. And the niche user base means even anecdotal data is thinner than average.

Intellectually, Humanin may be the most compelling longevity peptide on this list. Practically, it's among the least proven.

FAQ

What is Humanin?

A 21-amino-acid mitochondrially-derived peptide discovered while searching for Alzheimer's neuroprotective factors. It protects cells from death across multiple tissue types.

What's the difference between Humanin and HNG?

HNG has a single amino acid substitution (S14G) that makes it \~1,000 times more potent. All commercial Humanin is HNG.

Do centenarians have higher Humanin levels?

Their children do. Offspring of centenarians have significantly higher circulating Humanin than age-matched controls. Correlation, not causation.

What's MOTS-c?

A related mitochondrial peptide from the same genome but with metabolic (not cytoprotective) focus. Different compound, different mechanism.

Has it been tested in humans?

Not in interventional trials. Human data is entirely observational (plasma level measurements, centenarian correlations).

How is it taken?

Subcutaneous injection or intranasal. No oral bioavailability.

Is it FDA-approved?

No. Research chemical only.

What's the strongest evidence for?

Alzheimer's-related neuroprotection in animal and cell models. The founding application and the best-characterized mechanism.